[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100574845":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":18,"centralContacts":22,"locations":27,"responsibleParty":49,"collaborators":10,"id":51,"slug":10,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":10,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":10,"enrollmentInfo":59,"targetDuration":10,"studyType":62,"phases":10,"briefSummary":63,"conditions":64,"keywords":67,"overallStatus":29,"whyStopped":10,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"IRCCS Azienda Ospedaliero-Universitaria di Bologna","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"Tuberculosis or mycobacteriosis Microbiologically confirmed cases",null,"Retrospective phase from 1 January 2012 to 31 May 2021",{"label":13,"type":10,"description":14,"interventionNames":10},"Latent tuberculosis infection cases","Retrospective phase, patients followed by infectious diseases clinics from 2017 to May 2021",{"label":16,"type":10,"description":17,"interventionNames":10},"Patients with suspected tuberculosis, non-tubercular mycobacteriosis or tubercular infection","Prospective phase from 1 June 2021 to 31 December 2026",[19],{"name":20,"affiliation":5,"role":21},"Paola Dal Monte, MD","PRINCIPAL_INVESTIGATOR",[23],{"name":20,"role":24,"phone":25,"phoneExt":10,"email":26},"CONTACT","0390512145293","paola.dalmonte@unibo.it",[28],{"facility":5,"status":29,"city":30,"state":10,"zip":31,"country":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"RECRUITING","Bologna","40138","Italy",{"type":34,"coordinates":35},"Point",[36,37],11.33875,44.49381,{"lat":37,"lon":36},[40,42,45,47],{"name":20,"role":24,"phone":41,"phoneExt":10,"email":26},"+390512145293",{"name":43,"role":44,"phone":10,"phoneExt":10,"email":10},"Giulia Lombardi","SUB_INVESTIGATOR",{"name":46,"role":44,"phone":10,"phoneExt":10,"email":10},"Francesco Bisognin",{"name":48,"role":44,"phone":10,"phoneExt":10,"email":10},"Marina Tadolini, PhD",{"type":50,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100574845",false,"NCT06764576","Patients With Tuberculosis, Mycobacteriosis or Latent Tuberculosis","Epidemiological, Demographic and Clinical Aspects of Patients With Tuberculosis, Mycobacteriosis or Infection Latent Tuberculosis","Inclusion Criteria:\n\n* age of 18 years or more,\n* clinical\u002Fradiological suspicion of TB or non-tubercular mycobacteriosis or ITBL for which sent to the Microbiology laboratory at least one biological sample for the mycobacteria and\u002For a blood sample for the IGRA test;\n* Obtaining informed consent.\n\nExclusion Criteria:\n\n* None","ALL","18 Years",{"count":60,"type":61},13000,"ESTIMATED","OBSERVATIONAL","In the last 30 years, tuberculosis (TB) has re-emerged in industrialised countries as a public health, with a decrease in incidence among the resident population and an increase in the burden of immigrants. Therefore, it becomes a priority to implement an effective TB control that relies on both rapid and reliable identification of active infections, with a adequate treatment and surveillance of resistance, but also on the identification of latent tuberculosis infections (ITBL) in populations at higher risk of progression to the active disease, representing a source of infection for the community.",[65,66],"Mycobacterial Infection","Tuberculosis (TB)",[68,69,70,71,72,73,74],"infection","mycobacterial","tuberculosis","diagnosis","latent tuberculosis infection","mycobacterial non-tubercular","microbiological tests","2025-01-02",{"date":77,"type":78},"2025-01-08","ACTUAL",{"date":80,"type":78},"2021-12-19",{"date":82,"type":61},"2026-12-31",{"name":5,"class":6},1]